Price
CHART BY
Frequently asked questions
What is Tango's market capitalization?
The market capitalization of Tango is $1.17B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Tango?
Tango's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.917. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Tango's stock?
Currently, 10 analysts cover Tango's stock, with a consensus target price of $13.25. Analyst ratings provide insights into the stock's expected performance.
What is Tango's revenue over the trailing twelve months?
Over the trailing twelve months, Tango reported a revenue of $66.50M.
What is the EBITDA for Tango?
Tango's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$107.91M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Tango?
Tango has a free cash flow of -$146.77M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Tango have, and what sector and industry does it belong to?
Tango employs approximately 155 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Tango's shares?
The free float of Tango is 88.66M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.17B
- EPS (TTM)
- -$0.917
- Free Float
- 88.66M
- Revenue (TTM)
- $66.50M
- EBITDA (TTM)
- -$107.91M
- Free Cashflow (TTM)
- -$146.77M
Pricing
- 52W span
- $1.05$11.19
Analyst Ratings
The price target is $13.25 and the stock is covered by 10 analysts.
Buy
9
Hold
1
Sell
0
Information
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
- Employees
- 155
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- TNGX
Fundamentals & EOD data from FactSet